在急性髓性白血病中,GATA2将干与化疗耐药性联系在一起
Fatemeh Alikarami1,2, Hongbo M Xie1,3, Simone S Riedel1,2,4
1Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
Blood
|January 22, 2025
概括
干细胞转录因子GATA2 (GATA结合蛋白2) 通过抑制p53介导的亡,促进急性髓性白血病 (AML) 中的化疗耐药性. 针对GATA2或其下游效应器RASSF4,可以克服AML患者的耐药性.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 与干细胞相关的细胞状态有助于急性髓性白血病 (AML) 中的化疗耐药性.
- 转录因子GATA结合蛋白2 (GATA2) 对于造血干细胞的发育和维护至关重要.
- 在AML中观察到GATA2表达的变化,并与患者的结局有关.
研究的目的:
- 阐明GATA2表达和AML中的化疗耐药性之间的机制联系.
- 研究GATA2在调节细胞亡和药物敏感性的作用.
- 探索针对GATA2-RASSF4-MDM2-p53轴的治疗策略.
主要方法:
- 在AML患者样本和小鼠模型中分析GATA2表达.
- 功能性研究涉及Gata2删除和Rassf4.4的淘汰/过度表达.
- 染色体免疫沉降测序 (ChIP-seq) 和RNA测序 (RNA-seq).
- 对多克索鲁比辛和努特林-3的药物敏感性的评估.
主要成果:
- 在AML中更高的GATA2表达与增加对多克索鲁比的耐药性相关.
- GATA2直接调节RASSF4的表达,这是MDM2的调节器 (鼠标双分钟2).
- 通过调节RASSF4,GATA2通过调节RASSF4抑制了p53介导的亡,而这种轴在人类AML中保留了.
- 过度表达RASSF4使AML细胞对化疗产生敏感性,而它的敲击会产生耐药性.
结论:
- 通过通过RASSF4.4抑制p53-依赖性亡,GATA2是AML中化疗耐药性的关键调解者.
- GATA2-RASSF4通路代表了克服AML药物耐药性的新型治疗标.
- 在高GATA2的AML中观察到多克索鲁比辛和努特林-3的协同效应,这表明了组合治疗的潜力.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


